For the Inventor, By the Inventor

Enter assignee name

Carlsbad, CA, United States of America

The Immune Response Corporation

USPTO Granted Patents = 33

% Expired Patents = 3.0

Forward Citations = 642

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Dennis J Carlo (20 out of 21 patents)

Steven W Brostoff (11 out of 12 patents)

Mark D Howell (9 out of 10 patents)

4. Jonas Salk (7 out of 7 patents)

5. Charles R Ill (3 out of 3 patents)

6. Scott Bidlingmaier (2 out of 2 patents)

7. William Soo Hoo (2 out of 2 patents)

8. Henry C Chiou (2 out of 2 patents)

9. Ronald B Luftig (2 out of 3 patents)

10. Christopher P Prior (2 out of 4 patents)

11. David M Weber (2 out of 2 patents)

12. Richard S Gore (2 out of 2 patents)

13. James J Harter (2 out of 2 patents)

14. Daniel P Gold (1 out of 10 patents)

15. Claire Q Yang (1 out of 1 patent)

Core Competencies:

HIV

Immunogenic Compositions

Cytokine Modulation

Gene Delivery

Peptides

Vaccination

Retroviral Disease

Pathogenic Responses

Interferon

T Cell Populations

Antiviral Agents

Polynucleotide-Carrier

33 patents: Sort by Forward Citations

1. 6737066 - HIV immunogenic compositions and methods (2004-05-18),

2. 6642028 - Vectors and genes exhibiting increased expression (2003-11-04),

3. 6557296 - Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor (2003-05-06),

4. 6482407 - Membrane-bound cytokine compositions comprising GM-CSF or an active fragment thereof and methods of modulating and an immune response using the same (2002-11-19),

5. 6464978 - Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations (2002-10-15),

6. 6413516 - Peptides and methods against psoriasis (2002-07-02),

7. 6331525 - Targeted delivery of genes encoding interferon (2001-12-18),

8. 6328976 - Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor (2001-12-11),

9. 6221352 - Method of preventing the proliferation of V&bgr;14 or V&bgr;17-Expressing T cells (2001-04-24),

10. 6207645 - Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations (2001-03-27),

11. 6159470 - Vaccination and methods against diseases resulting from pathogenic (2000-12-12),

12. 6113903 - Peptides and methods against diabetes (2000-09-05),

13. 6090387 - Vaccination and methods against diseases resulting from pathogenic (2000-07-18),

14. 6080571 - Highly efficient production and isolation of viral particles utilizing (2000-06-27),

15. 6069133 - Targeted delivery of genes encoding interferon (2000-05-30),

The Immune Response Corporation, based in Carlsbad, California, specializes in developing innovative immunotherapies aimed at treating various diseases, including cancer and autoimmune disorders. The organization focuses on harnessing the body's immune system to create effective therapeutic solutions, leveraging advanced research in immunology and biotechnology. With a commitment to scientific excellence, the company aims to improve patient outcomes through its cutting-edge technologies and collaborative research efforts.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

33 Patents

#43 in Carlsbad, CA

#2,458 in California

#10,288 in US

#20,112 in the World

Carlsbad, CA, United States of America

The Immune Response Corporation

Forward Citations = 642

32 inventors:

Dennis J Carlo (20 out of 21 patents)

Steven W Brostoff (11 out of 12 patents)

Mark D Howell (9 out of 10 patents)

4. Jonas Salk (7 out of 7 patents)

5. Charles R Ill (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…